Probable carvedilol-induced thrombocytopenia

Alex, Sumana; Chang Chretien, Katherine; Cho, Alexander; Aggarwal, Anita
April 2013
American Journal of Health-System Pharmacy;4/1/2013, Vol. 70 Issue 7, p598
Academic Journal
Purpose. A case of probable carvedilol-induced thrombocytopenia is reported. Summary. A 64-year-old African-American woman with a history of hypertension, diastolic dysfunction, mild left-ventricular hypertrophy, and pulmonary embolism was hospitalized with a platelet count of 94,000 platelets/mm3. Dalteparin, warfarin, and carvedilol had recently been added to her medication regimen. Beta-2-glycoprotein immunoglobulin G (IgG) antibody, anticardiolipin IgG, and anticardiolipin immunoglobulin M tests, conducted to rule out antiphospholipid syndrome, revealed values within the normal range. After the exclusion of dalteparin, hydrochlorothiazide, and other causes of drug- and non-drug-related thrombocytopenia, carvedilol was discontinued and replaced with metoprolol tartrate. After this substitution, the patient’s platelet count continued to rise. On hospital day 10, the patient was discharged to home on low-molecular-weight heparin bridging therapy, warfarin sodium 5 mg orally daily, ranitidine 150 mg orally daily, metoprolol tartrate 75 mg orally twice daily, lisinopril 20 mg orally daily, amlodipine 10 mg orally daily, cyanocobalamin 1000 g orally daily, and two tablets of hydrochlorothiazide 25 mg–triamterene 37.5 mg orally daily. Her platelet count was 319,000 platelets/mm3 on the day of discharge and remained stable thereafter. The recovery time of the platelets coincided with the elimination half-life of carvedilol. Conclusion. A woman developed thrombocytopenia, first noticed as a reduction in the platelet count to a low-normal value, 17 days after treatment with carvedilol was begun. Other possible culprit drugs were withdrawn, but the platelet count continued to drop until carvedilol was discontinued. The platelet count rose on the day of carvedilol removal and was within the normal range within another day.


Related Articles

  • Effects of Carteolol Hydrochloride on the In Vitro Production of LPS-Induced Proinflammatory Cytokines by Murine Macrophage. Kawai, Kenji; Kuwahara, Keiichi; Oizumi, Nobuyuki; Kitagaki, Hideki; Fujisawa, Shigeki // Journal of Ocular Pharmacology & Therapeutics;Jun2004, Vol. 20 Issue 3, p237 

    We investigated whether carteolol hydrochloride, which has intrinsic sympathomimetic activity (ISA), inhibits the production of proinflammatory cytokines using mouse macrophages (MPs) and peripheral-blood mononuclear cells (PBMCs). MPs and PBMCs were collected from BALB/C strain mice, treated...

  • Betaloc.  // Royal Society of Medicine: Medicines;2002, p111 

    The article presents information on Betaloc, a proprietary, prescription-only preparation drug of the beta-blocker metoprolol tartrate. This drug can be used as an antihypertensive for high blood pressure, as an anti-angina treatment to relieve symptoms and improve exercise tolerance...

  • Betaloc-SA.  // Royal Society of Medicine: Medicines;2002, p112 

    The article presents information on Betaloc-SA, a proprietary, prescription-only preparation drug of the beta-blocker metoprolol tartrate. This drug can be used as an antihypertensive for high blood pressure and as an antimigraine treatment to prevent attacks.

  • Review: β-blockers are less effective than other antihypertensive drugs for reducing risk for stroke in primary hypertension: COMMENTARY. Rudd, Peter // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p67 

    The article presents comments of the author on a study which found that β-blockers are less effective than other antihypertensive drugs for reducing risk for stroke in primary hypertension. Despite their traditional place in antihypertensive pharmacology, β-blockers have received mixed...

  • Effect of blood pressure on plasma volume loss in the rat under increased permeability. Dubniks, Maris; Persson, Johan; Grände, Per-Olof; Grände, Per-Olof // Intensive Care Medicine;Dec2007, Vol. 33 Issue 12, p2192 

    Objective: To evaluate the effects of change in blood pressure on plasma volume under increased permeability.Design: Prospective randomized laboratory study.Subject: Sixty-one adult male Sprague-Dawley rats.Interventions: Permeability was...

  • A comparison of beta-blockers in heart failure. Pinkowish, Mary Desmond // Patient Care for the Nurse Practitioner;Oct2000, Vol. 3 Issue 10, p16 

    Features a comparative study on the long-term effects of metoprolol and carvedilol, beta blockers, in patients with heart failure. Aims of the study; Study design; Findings of the study.

  • Nebivolol: A unique drug in acute and chronic renal disorders. Amiri, Fateme Shamekhi // Indian Journal of Pharmacology;Jul/Aug2015, Vol. 47 Issue 4, p462 

    A letter to the editor is presented in response to the article "Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta-blockers?" in the 2014 issue.

  • WHAT'S NEW IN DRUGS.  // RN;Nov78, Vol. 41 Issue 11, p35 

    Reports on the approval for the marketing of the beta-blocking agent metoprolol tartrate for the treatment of hypertension in the U.S. as of November 1978. Indications and contraindications; Drug mechanism; Interaction with other drugs.

  • Successful Treatment of Supraventricular Tachycardia with Metoprolol, a Cardioselective Beta Blocker. Hepner, Seymour I.; Davoli, Enrico // Clinical Pediatrics;Jul1983, Vol. 22 Issue 7, p522 

    Paroxysmal supraventricular tachycardia is a common problem in infancy and childhood. Past treatment has included digitalis and nonselective beta blockers (propranolol). We describe a new mode of therapy with a cardioselective beta blocker (metoprolol) that may be of use in patients resistant to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics